Silence Therapeutics plc

SLN

US82686Q1013

Market Closed - Nasdaq Other stock markets 10:30:00 03/07/2024 pm IST			5-day change	1st Jan Change
17.97 ^USD	-0.50%		-1.86%	+3.45%

02/07	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
28/06	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Silence Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	02/07	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	28/06	MT
Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating	28/06	MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating	28/06	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	27/06	MT
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	27/06	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	27/06	MT
Silence Therapeutics Says Divesiran Shows Sustained Hematocrit Reduction in Blood Cancer Study	27/06	MT
Transcript : Silence Therapeutics plc - Special Call	27/06
Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	27/06	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	26/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	21/06	MT
Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)	20/06	CI
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	17/06	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	12/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	30/05	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	28/05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	22/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	21/05	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	17/05	MT
Silence Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	16/05	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	15/05	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	13/05	MT

Chart Silence Therapeutics plc

Duration

Period

More charts

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is focused on discovering and developing molecules incorporating short-interfering ribonucleic acid (siRNA) to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body's natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target disease-associated genes in the liver. Its wholly owned product candidates include SLN360, for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein (a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).

Sector

Calendar

12/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company